Milestones for ELPEN

1965

FOUNDATION

59 years ago, a small team of scientists, led by a visionary pharmacist, with limited financial resources, set the foundation for a modern and dynamic pharmaceutical company

1970

INDUSTRIAL SITE

ELPEN establishes its own production facilities, which transform the company into a leading player in the Greek pharmaceutical market. the company owns over 10,000 m2 facilities, which operate according to inetrnational GMP and ISO standards

1990

INTERNATIONAL SALES

The company wins its first major Tender and place its product in the private market with the aid of selected partners

2002

ELPENHALER®

is ELPEN's proprietary, patent protected, breath-activated, multi single-dose dry powder inhaler

2009

ROLENIUM

ROLENIUM is ELPEN's fluticasone/salmeterol hybrid combination for the treatment of asthma & COPD, launched in Greece in Nov. 2009

2012

ELPEN PHARMA GmbH

ELPEN PHARMA GmbH subsidiary founded in Feb. 2012 in Berlin, Germany

2014

B2B ACTIVITIES

ELPEN's International Business Division is created with the aim to consolidate its position as a preferred partner for the licensing and supply of Finished Dosage Forms

2016

CHC/OTC LINE

Expansion of ELPEN's activities in Consumer Health Care products

2018

DEVELOPMENT

• New product development
• Export activity enhancement

2019

STRATEGIC INVESTMENTS

• Expansion of R&D and modernization of production facilities (Pikermi)
• New production facility (Keratea)
• Biotechnology Park - Athens LifeTech Park (Spata)

2021

COMBINATION OF STATINS & EZETIMIBE

Launched in Europe

2024

ELPEN Middle East Africa

ELPEN Middle East Africa subsidiary founded in June 2024 in Dubai, UAE